{"database": "lobbying", "table": "lobbying_activities", "rows": [[2683910, "d207093d-26aa-471c-a1bc-1d48d99ec587", "Q3", "MEHLMAN CONSULTING, INC.", 284950, "AMNEAL", 2021, "third_quarter", "MAN", "Monitoring legislative and regulatory efforts related to domestic manufacturing of generic drugs.\nS.1176 - Onshoring Essential Antibiotics Act.\nThe Build Back Better Act, a bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14.\nPandemic Preparedness.", "Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 60000, null, 0, 0, "2021-10-18T09:37:51.060000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2683910"], "units": {}, "query_ms": 106.3396017998457, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}